痛风：优化治疗以实现疾病治愈
Gout: optimizing treatment to achieve a disease cure.
作者信息
Bernal José Antonio, Quilis Neus, Andrés Mariano, Sivera Francisca, Pascual Eliseo
机构信息
Sección de Reumatología, Hospital General Universitario de Alicante, Pintor Baeza 12, Alicante, 03010, Spain.
Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain.
出版信息
Ther Adv Chronic Dis. 2016 Mar;7(2):135-44. doi: 10.1177/2040622315618393. Epub 2016 Jan 12.
Abstract
Gout is one of the most common inflammatory arthritides. The disease is due to the deposition of monosodium urate crystals. These deposits are reversible with proper treatment, suggesting that gout is a curable disease. The main aim in gout is to lower serum uric acid levels to a pre-established target; there are different urate-lowering drugs (xanthine oxidase inhibitors, uricosurics and uricases) through which this can be achieved. Proper treatment of gout also involves correct management of acute flares and their prevention. To ensure treatment adherence it is necessary to explain to the patient what the objectives are.
摘要
痛风是最常见的炎性关节炎之一。该病是由于尿酸钠晶体沉积所致。通过适当治疗，这些沉积物是可逆的，这表明痛风是一种可治愈的疾病。痛风治疗的主要目标是将血清尿酸水平降至预先设定的目标；有不同的降尿酸药物（黄嘌呤氧化酶抑制剂、促尿酸排泄药和尿酸酶）可实现这一目标。痛风的恰当治疗还包括对急性发作的正确管理及其预防。为确保患者坚持治疗，有必要向患者解释治疗目标。
相似文献
1
Gout: optimizing treatment to achieve a disease cure.痛风：优化治疗以实现疾病治愈
Ther Adv Chronic Dis. 2016 Mar;7(2):135-44. doi: 10.1177/2040622315618393. Epub 2016 Jan 12.
2
Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.痛风治疗的最新进展，包括对更新的治疗指南的回顾以及小分子疗法在难治性痛风和痛风发作治疗中的应用。
Expert Opin Pharmacother. 2017 Aug;18(11):1115-1125. doi: 10.1080/14656566.2017.1349099. Epub 2017 Jul 9.
3
Current and future therapies for gout.痛风的当前及未来治疗方法
Expert Opin Pharmacother. 2017 Aug;18(12):1201-1211. doi: 10.1080/14656566.2017.1351945. Epub 2017 Jul 28.
4
Advances in pharmacotherapy for the treatment of gout.痛风治疗的药物疗法进展
Expert Opin Pharmacother. 2015 Mar;16(4):533-46. doi: 10.1517/14656566.2015.997213. Epub 2014 Dec 30.
5
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.新兴的降尿酸药物和痛风的药物治疗策略：一篇叙述性综述。
Drugs. 2023 Nov;83(16):1501-1521. doi: 10.1007/s40265-023-01944-y. Epub 2023 Oct 11.
6
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).双能计算机断层扫描（DECT）显示的厌食症患者的痛风石性痛风
Am J Case Rep. 2016 Jul 15;17:494-8. doi: 10.12659/ajcr.898542.
7
The challenges of gout management in the elderly.老年人痛风管理面临的挑战。
Drugs Aging. 2011 Aug 1;28(8):591-603. doi: 10.2165/11592750-000000000-00000.
8
Gout--what are the treatment options?痛风——有哪些治疗选择？
Expert Opin Pharmacother. 2009 Jun;10(8):1319-28. doi: 10.1517/14656560902950742.
9
Novel uricosurics.新型黄嘌呤氧化酶抑制剂。
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i42-i46. doi: 10.1093/rheumatology/kex433.
10
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.基层医疗环境中治疗痛风和晶体沉积的当前护理标准的局限性：一项综述
Clin Ther. 2017 Feb;39(2):430-441. doi: 10.1016/j.clinthera.2016.12.011. Epub 2017 Jan 11.
引用本文的文献
1
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.降尿酸治疗达标治疗对痛风患者血清尿酸目标达成的影响因素。
Arthritis Rheumatol. 2024 Apr;76(4):638-646. doi: 10.1002/art.42731. Epub 2023 Dec 26.
2
Identification of xanthine oxidase inhibitors through hierarchical virtual screening.通过分层虚拟筛选鉴定黄嘌呤氧化酶抑制剂
RSC Adv. 2020 Jul 24;10(46):27752-27763. doi: 10.1039/d0ra03143g. eCollection 2020 Jul 21.
3
The Effect of Low and Moderate Exercise on Hyperuricemia: Protocol for a Randomized Controlled Study.低强度和中等强度运动对高尿酸血症的影响：一项随机对照研究方案。
Front Endocrinol (Lausanne). 2021 Sep 2;12:716802. doi: 10.3389/fendo.2021.716802. eCollection 2021.
4
Incident gout and weight change patterns: a retrospective cohort study of US adults.事件性痛风与体重变化模式：一项美国成年人的回顾性队列研究。
Arthritis Res Ther. 2021 Mar 2;23(1):69. doi: 10.1186/s13075-021-02461-7.
5
Therapeutic Efficacy of Urinile Against Gouty Arthritis.尿宁对痛风性关节炎的治疗效果
Dose Response. 2020 Oct 4;18(4):1559325820946934. doi: 10.1177/1559325820946934. eCollection 2020 Oct-Dec.
6
Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.系统结构-活性关系（SAR）研究二芳基甲烷骨架及发现高效新型尿酸盐转运蛋白 1（URAT1）抑制剂。
Molecules. 2018 Jan 27;23(2):252. doi: 10.3390/molecules23020252.
7
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.超重和肥胖痛风患者的体重减轻：纵向研究的系统评价
Ann Rheum Dis. 2017 Nov;76(11):1870-1882. doi: 10.1136/annrheumdis-2017-211472. Epub 2017 Sep 2.
8
Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor.发现一种柔性三唑基丁酸作为高效尿酸转运蛋白1（URAT1）抑制剂
Molecules. 2016 Nov 16;21(11):1543. doi: 10.3390/molecules21111543.
9
Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.综述：痛风：改善全球治疗效果的方法指南
Arthritis Rheumatol. 2017 Jan;69(1):22-34. doi: 10.1002/art.39799.
本文引用的文献
1
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.Lesinurad，一种选择性尿酸重吸收抑制剂，与非布司他联合用于尿酸盐结石型痛风患者：III 期临床试验结果。
Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.
2
Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.依托考昔与非甾体抗炎药治疗急性痛风的疗效和安全性：一项系统评价和荟萃分析。
Clin Rheumatol. 2016 Jan;35(1):151-8. doi: 10.1007/s10067-015-2991-1. Epub 2015 Jun 24.
3
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.非布司他与别嘌醇降低痛风患者尿酸水平的疗效比较：来自美国大型管理式医疗队列的分析
Arthritis Res Ther. 2015 May 12;17(1):120. doi: 10.1186/s13075-015-0624-3.
4
Does starting allopurinol prolong acute treated gout? A randomized clinical trial.开始使用别嘌醇会延长急性痛风的治疗时间吗？一项随机临床试验。
J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.
5
Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study.非布司他在日常实践中用于降尿酸治疗——一项多中心、开放标签、前瞻性观察性研究
Int J Rheumatol. 2014;2014:123105. doi: 10.1155/2014/123105. Epub 2014 Sep 3.
6
Non-steroidal anti-inflammatory drugs for acute gout.用于急性痛风的非甾体抗炎药。
Cochrane Database Syst Rev. 2014 Sep 16(9):CD010120. doi: 10.1002/14651858.CD010120.pub2.
7
Interleukin-1 inhibitors for acute gout.用于急性痛风的白细胞介素-1抑制剂
Cochrane Database Syst Rev. 2014 Sep 1;2014(9):CD009993. doi: 10.1002/14651858.CD009993.pub2.
8
ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action.ACTH 治疗急性晶体诱导性关节炎：临床证据和作用机制的更新。
Semin Arthritis Rheum. 2014 Apr;43(5):648-53. doi: 10.1016/j.semarthrit.2013.09.006. Epub 2013 Oct 5.
9
Epidemiology of gout.痛风的流行病学
Rheum Dis Clin North Am. 2014 May;40(2):155-75. doi: 10.1016/j.rdc.2014.01.001. Epub 2014 Feb 19.
10
Treatment of acute gout: a systematic review.急性痛风的治疗：一项系统评价。
Semin Arthritis Rheum. 2014 Aug;44(1):31-8. doi: 10.1016/j.semarthrit.2014.02.003. Epub 2014 Feb 13.
Zotero 插件